Data on VIVUS' Qnexa to Be Presented at the European Society of Cardiology Congress

 

MOUNTAIN VIEW, Calif., Aug 25 /PRNewswire-FirstCall/ -- VIVUS, Inc. (NASDAQ:VVUS) today announced that data on Qnexa®, an investigational drug candidate, will be featured in two poster presentations at the European Society of Cardiology Congress Spotlight: Coronary Artery Disease , being held in Stockholm, Sweden from August 28 - September 1, 2010 at the Stockholmsmassan. Serena Tonstad, MD, PhD, MPH will deliver a poster presentation entitled, "Low-Dose, Controlled-Release Phentermine/Topiramate Improves Cardiovascular Disease Risk Factors" on Tuesday, August 31st at 3:30 - 4:30 pm CET. Michael Davidson, MD will deliver a poster presentation entitled, "Low-Dose, Controlled-Release Phentermine/Topiramate Mediated Weight Loss Causes Improvements in Lipoproteins and Inflammatory Biomarkers in Overweight Patients With Comorbidities" on Wednesday, September 1st at 10:00 - 11:00 am CET.
 

  Following are details about the upcoming poster presentations:



  European Society of Cardiology Congress Spotlight: Coronary Artery
   Disease in Stockholm, Sweden
  ------------------------------------------------------------------

  Date and Time: Tuesday, August 31, 2010, 3:30-4:30 pm CET
  Session: Poster session 6: Cardiovascular risk
  Poster #: 5457, Poster Zone A
  Poster Presentation Title: Low-Dose, Controlled-Release Phentermine/
   Topiramate (PHEN/TPM) Improves Cardiovascular Disease (CVD) Risk
   Factors
  Presenter: Serena Tonstad, MD, PhD, MPH
  Co-Authors: Michael Davidson, MD; Craig Peterson, MS; Barbara Troupin,
   MD

  Date and Time: Wednesday, September 1, 2010, 10:00-11:00 am CET
  Session: Poster session 7: Overweight, obesity and metabolic syndrome
  Poster #: 4676, Poster Zone A
  Poster Presentation Title: Low-Dose, Controlled-Release Phentermine/
   Topiramate (PHEN/TPM) Mediated Weight Loss Causes Improvements in
   Lipoproteins and Inflammatory Biomarkers in Overweight Patients With
   Comorbidities
  Presenter: Michael Davidson, MD
  Co-Authors: Serena Tonstad, MD, PhD, MPH; Chuck Bowden, MD; Wesley
   Day, PhD


  About VIVUS

VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.
 

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2009 and periodic reports filed with the Securities and Exchange Commission.
 

  CONTACT:
  --------

  VIVUS, Inc.           Investor Relations:       The Trout Group
  Timothy E. Morris                               Brian Korb
  Chief Financial
   Officer                                        646-378-2923
  650-934-5200
                        Media Relations:          Pure Communications, Inc.
                                                  Dan Budwick
                                                  973-271-6085

Source: VIVUS, Inc.

CONTACT: Timothy E. Morris, Chief Financial Officer of VIVUS, Inc.,
+1-650-934-5200; or Investor Relations, Brian Korb of The Trout Group,
+1-646-378-2923; or Media Relations, Dan Budwick of Pure Communications,
Inc., +1-973-271-6085
 

Web Site: http://www.vivus.com/
 

Posted: August 2010

View comments

Hide
(web4)